Stocktoria
Ensysce Biosciences, Inc. ENSC
Nasdaq · stock · Pharmaceutical Preparations · website · IPO 2017-12-01
Ensysce Biosciences, Inc. statistics & valuation
Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else from the latest financial reports.
Profitability & efficiency
Margins and returns computed from annual filings. Falling shares outstanding = buybacks; rising = dilution. Net debt = debt − cash (negative = net cash).
Key ratios (by fiscal year)
| Ratio | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Operating margin | -202.1% | -129.2% | -480.5% | -959.9% | -562.7% | -41.0% | — | — |
| Net margin | — | — | — | — | — | 61.2% | — | — |
| FCF margin | -156.5% | — | — | — | — | — | — | — |
| Return on assets | — | — | — | — | — | 683.5% | 0.2% | 1.0% |
| Return on equity | — | — | — | — | — | -36.1% | -5.5% | 42.4% |
| Current ratio | 1.59 | 2.42 | 0.69 | 0.56 | 0.95 | 0.05 | 0.43 | 4.38 |
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.